Celiac Disease is being explored in depth in San Diego at Digestive Disease Week (DDW), the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
By Amy Ratner, Medical and Science News Analyst
Celiac Disease is being explored in depth today in San Diego at Digestive Disease Week (DDW), the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
In a series of talks under the broad topic of celiac disease and related disorders, experts will discuss their latest work on topics including how well symptoms predict the results of blood tests used to monitor celiac disease and what results of stool and urine tests for a component of gluten tell us about the way patients handle the gluten-free diet in real life.
The work of Marie Robert, MD, chief scientific officer for Beyond Celiac and professor of pathology and medicine at Yale University School of Medicine, on how to correctly take samples when a patient needs a second biopsy so changes are not missed and how symptoms correlate with the biopsy findings is being presented.
In a clinical controversy debate, experts will present two sides of the question of whether patients with minimal or no symptoms should be screened for celiac disease. In that session, the economic burden of celiac disease will also be explored.
Additionally, throughout the afternoon, researchers will present posters that detail work that is in progress. Robert also has a poster presentation related to her lecture that shows symptoms, adherence to the gluten-free diet and blood test results do not reliably predict intestinal healing in a follow-up biopsy.
Other topics include how:
• often celiac disease patients use healthcare
• a diagnosis of celiac disease of one member ripples through a family
• minimally invasive monitoring of intestinal health in patients recovering from celiac disease
• latiglutenase, a drug under study for celiac disease, reduced symptoms
• celiac disease patients are followed up
A second day of celiac disease programs is scheduled for Tuesday.
DDW gives practicing physicians and researchers an opportunity to look at the broad scope of their fields and apply what they discover to the treatment of patients or research projects.
Opt-in to stay up-to-date on the latest news.Yes, I want to advance research No, I'd prefer not to